Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -86.67% | 1.74% | -6.75% | 1.75% | 0.02% |
| Total Depreciation and Amortization | 79.92% | -19.74% | 21.57% | -2.33% | -0.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.25% | 61.00% | -8.43% | -19.83% | 33.30% |
| Change in Net Operating Assets | 126.86% | 125.97% | 71.84% | -223.43% | -152.58% |
| Cash from Operations | -94.90% | 27.97% | 19.63% | -38.10% | -1.59% |
| Capital Expenditure | 71.55% | -285.96% | 82.23% | -221.87% | -177.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | -187.94% |
| Cash from Investing | 6,138.05% | -9.09% | 37.14% | -167.40% | -617.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 8.13% | -8,696.15% | 0.00% | 96.25% | -2,791.67% |
| Issuance of Common Stock | -32.05% | -92.88% | 1,790.02% | -82.89% | 51.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -35.37% | -93.74% | 1,793.37% | -82.77% | 50.02% |
| Foreign Exchange rate Adjustments | -961.54% | 441.53% | 46.12% | -276.61% | 207.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 456.32% | -126.57% | 285.36% | -2,358.77% | 121.50% |
